$CLRB
Cellectar Biosciences, Inc.

2014 Q4 Form 10-Q Financial Statement

#000114420414066769 Filed on November 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $850.0K $800.0K $840.0K
YoY Change -39.72% -4.76% 5.0%
% of Gross Profit
Research & Development $1.400M $1.470M $2.067M
YoY Change -9.68% -28.86% 64.94%
% of Gross Profit
Depreciation & Amortization $90.00K $90.00K $110.0K
YoY Change 0.0% -18.18% 0.0%
% of Gross Profit
Operating Expenses $2.250M $1.470M $2.067M
YoY Change -23.99% -28.86% 64.94%
Operating Profit -$2.273M -$2.910M
YoY Change -21.9% 41.7%
Interest Expense -$1.090M -$253.1K -$2.241K
YoY Change -1090.91% 11192.19% 6.92%
% of Operating Profit
Other Income/Expense, Net $2.597M $1.595M
YoY Change 62.82% 88223.98%
Pretax Income -$3.350M $320.0K -$1.320M
YoY Change -15.19% -124.24% -35.61%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.350M $324.0K -$1.315M
YoY Change -15.19% -124.63% -35.91%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$41.88M $6.400M -$44.00M
COMMON SHARES
Basic Shares Outstanding 7.563M shares 57.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.420M $11.58M $5.110M
YoY Change 289.26% 126.61% -8.75%
Cash & Equivalents $9.423M $11.58M $5.110M
Short-Term Investments
Other Short-Term Assets $280.0K $350.0K $390.0K
YoY Change -20.0% -10.26% -2.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.698M $11.92M $5.495M
YoY Change 250.36% 116.96% -8.27%
LONG-TERM ASSETS
Property, Plant & Equipment $2.034M $2.111M $2.450M
YoY Change -13.84% -13.82% -9.27%
Goodwill $1.675M $1.675M $1.675M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.87K $11.87K $27.22K
YoY Change 0.0% -56.39% -9.26%
Total Long-Term Assets $3.721M $3.799M $4.152M
YoY Change -8.07% -8.52% -5.63%
TOTAL ASSETS
Total Short-Term Assets $9.698M $11.92M $5.495M
Total Long-Term Assets $3.721M $3.799M $4.152M
Total Assets $13.42M $15.72M $9.647M
YoY Change 96.88% 62.95% -7.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $930.0K $1.140M $1.160M
YoY Change -19.83% -1.72% 63.38%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $120.0K $110.0K $0.00
YoY Change
Total Short-Term Liabilities $6.233M $2.065M $4.629M
YoY Change 37.8% -55.39% 525.56%
LONG-TERM LIABILITIES
Long-Term Debt $340.0K $360.0K $450.0K
YoY Change -24.44% -20.0% 0.0%
Other Long-Term Liabilities $150.0K $150.0K $140.0K
YoY Change 7.14% 7.14% 7.69%
Total Long-Term Liabilities $489.0K $505.1K $591.9K
YoY Change -17.57% -14.66% 2.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.233M $2.065M $4.629M
Total Long-Term Liabilities $489.0K $505.1K $591.9K
Total Liabilities $6.722M $2.570M $5.221M
YoY Change 31.38% -50.77% 295.53%
SHAREHOLDERS EQUITY
Retained Earnings -$59.11M -$56.59M
YoY Change 15.77%
Common Stock $76.00 $76.00 $574.00
YoY Change 162.07% -86.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.698M $13.15M $4.426M
YoY Change
Total Liabilities & Shareholders Equity $13.42M $15.72M $9.647M
YoY Change 96.88% 62.95% -7.15%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$3.350M $324.0K -$1.315M
YoY Change -15.19% -124.63% -35.91%
Depreciation, Depletion And Amortization $90.00K $90.00K $110.0K
YoY Change 0.0% -18.18% 0.0%
Cash From Operating Activities -$2.140M -$2.100M -$2.560M
YoY Change -19.85% -17.97% 51.48%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 -$40.00K
YoY Change -50.0% -100.0% 300.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $1.880M
YoY Change -100.0%
Cash From Investing Activities -$10.00K $0.00 $1.840M
YoY Change -50.0% -100.0% -18500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 12.04M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.140M -2.100M -2.560M
Cash From Investing Activities -10.00K 0.000 1.840M
Cash From Financing Activities 0.000 12.04M 0.000
Net Change In Cash -2.150M 9.940M -720.0K
YoY Change -20.07% -1480.56% -53.55%
FREE CASH FLOW
Cash From Operating Activities -$2.140M -$2.100M -$2.560M
Capital Expenditures -$10.00K $0.00 -$40.00K
Free Cash Flow -$2.130M -$2.100M -$2.520M
YoY Change -19.62% -16.67% 50.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.1 pure
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y1M20D
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
275000 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11576005 USD
CY2014Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
55000 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
290352 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
11921357 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
2768071 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2111280 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2360534 USD
CY2014Q3 us-gaap Goodwill
Goodwill
1675462 USD
CY2013Q4 us-gaap Goodwill
Goodwill
1675462 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872 USD
CY2014Q3 us-gaap Assets
Assets
15719971 USD
CY2013Q4 us-gaap Assets
Assets
6815939 USD
CY2014Q3 us-gaap Notes Payable Current
NotesPayableCurrent
103325 USD
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1139503 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1162098 USD
CY2014Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
820124 USD
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3359363 USD
CY2014Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2122 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1694 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2065074 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4523155 USD
CY2014Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
346675 USD
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
450000 USD
CY2014Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
147234 USD
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
143234 USD
CY2014Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
505093 USD
CY2014Q3 us-gaap Liabilities
Liabilities
2570167 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Liabilities
Liabilities
5116389 USD
CY2013Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
593234 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
76 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
29 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69744261 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52759089 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56594533 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51059568 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
13149804 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
1699550 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15719971 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6815939 USD
CY2014Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2013Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2014Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
551365 shares
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
826365 shares
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0092 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0107 pure
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.09 pure
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P3Y7M20D
CY2014Q1 us-gaap Convertible Debt
ConvertibleDebt
4000000 USD
CY2014Q1 clrb Convertible Debentures And Warrants To Purchase Common Stock
ConvertibleDebenturesAndWarrantsToPurchaseCommonStock
400000 shares
CY2014Q1 clrb Payment For Convertible Debentures
PaymentForConvertibleDebentures
4000000 USD
CY2014Q1 clrb Securities Purchase Agreement Initiation Date
SecuritiesPurchaseAgreementInitiationDate
2014-02-05
CY2014Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2014-02-06
CY2014Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.00
CY2014Q1 clrb Gross Proceeds From Sale Of Securities
GrossProceedsFromSaleOfSecurities
2000000 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
20.00
CY2014Q1 clrb Warrants Expiration Date
WarrantsExpirationDate
2019-02-06
CY2014Q1 clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
254000 USD
CY2014Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3746000 USD
CY2014Q3 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
172000 USD
CY2014Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
254000 USD
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt.
clrb Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
1-for-20
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2014Q3 clrb Common Stock Shares Previously Authorized
CommonStockSharesPreviouslyAuthorized
150000000 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6604096 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7562762 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2869739 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7562762 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2869739 shares
us-gaap Share Based Compensation
ShareBasedCompensation
1101465 USD
us-gaap Share Based Compensation
ShareBasedCompensation
682775 USD
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
146559 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.09 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0176 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
20000 shares
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
21018 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14474 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
278051 shares
CY2014Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
341115 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
278051 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.07
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.40
clrb Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
19.57
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.00
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.64
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
27.98
CY2014Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
9.21
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y14D
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P9Y7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y14D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2014Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
0 USD
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
1094000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
562000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
193000 USD
CY2014Q3 clrb Weighted Average Grant Date Fair Value Of Vested Options Outstanding
WeightedAverageGrantDateFairValueOfVestedOptionsOutstanding
16.23
CY2014Q3 clrb Weighted Average Grant Date Fair Value Of Unvested Options Outstanding
WeightedAverageGrantDateFairValueOfUnvestedOptionsOutstanding
5.90
CY2014Q3 clrb Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber
259310 shares
clrb Estimated Stock Based Compensation Expense Up On Vesting Of Options
EstimatedStockBasedCompensationExpenseUpOnVestingOfOptions
418000 USD
CY2014Q1 clrb Antidilution Option Reduced By Expiration Of Warrants
AntidilutionOptionReducedByExpirationOfWarrants
14474 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
CY2013Q4 clrb Antidilution Option Reduced Rate
AntidilutionOptionReducedRate
19 shares
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1849000 USD
clrb Payment Of Lump Sum Amount Related To Employment Agreement
PaymentOfLumpSumAmountRelatedToEmploymentAgreement
160000 USD
clrb Amount Invoiced Under Clinical Trial Agreements
AmountInvoicedUnderClinicalTrialAgreements
486000 USD
clrb Payment Towards Clinical Trial Agreements
PaymentTowardsClinicalTrialAgreements
469000 USD
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
62500 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5306277 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4566403 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2066827 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1470297 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3039074 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2849714 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
843622 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
802794 USD
us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Restructuring Costs
RestructuringCosts
221815 USD
CY2013Q3 us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2014Q3 us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Costs And Expenses
CostsAndExpenses
8345351 USD
us-gaap Costs And Expenses
CostsAndExpenses
7637932 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
2910449 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
2273091 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8345351 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7637932 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2910449 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2273091 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
2263756 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
2539239 USD
CY2013Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
1597372 USD
CY2014Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
2020433 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-744957 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2013Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2014Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7107 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-436272 USD
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2241 USD
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-253058 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1511692 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2102967 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1595131 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1767375 USD
us-gaap Net Income Loss
NetIncomeLoss
-6833659 USD
us-gaap Net Income Loss
NetIncomeLoss
-5534965 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1315318 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-505716 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2769167 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3591742 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2869739 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5012206 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
325660 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
277688 USD
clrb Noncash Interest Expense Related To Discount On Convertible Debt
NoncashInterestExpenseRelatedToDiscountOnConvertibleDebt
0 USD
clrb Noncash Interest Expense Related To Discount On Convertible Debt
NoncashInterestExpenseRelatedToDiscountOnConvertibleDebt
426458 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4513 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2269 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
440323 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-22594 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1959 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4335 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-6450 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-4000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6476006 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6699273 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
134956 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17397 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1865044 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17397 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
0 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
1158 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12395965 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
70539 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5043910 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15874291 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
432948 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9157621 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4677545 USD
clrb Fair Value Of Warrants Classified As Derivative Liability
FairValueOfWarrantsClassifiedAsDerivativeLiability
5720000 USD
clrb Fair Value Of Warrants Classified As Derivative Liability
FairValueOfWarrantsClassifiedAsDerivativeLiability
0 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
0 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
254024 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CLRB
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7562762 shares
CY2014Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
11184 USD
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
617500 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
617500 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
518822 USD
CY2014Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13475832 USD
CY2014Q3 us-gaap Proceeds From Repurchase Of Equity
ProceedsFromRepurchaseOfEquity
11877143 USD
CY2014Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1598689 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
4172444 USD

Files In Submission

Name View Source Status
0001144204-14-066769-index-headers.html Edgar Link pending
0001144204-14-066769-index.html Edgar Link pending
0001144204-14-066769.txt Edgar Link pending
0001144204-14-066769-xbrl.zip Edgar Link pending
clrb-20140930.xml Edgar Link completed
clrb-20140930.xsd Edgar Link pending
clrb-20140930_cal.xml Edgar Link unprocessable
clrb-20140930_def.xml Edgar Link unprocessable
clrb-20140930_lab.xml Edgar Link unprocessable
clrb-20140930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v393175_10q.htm Edgar Link pending
v393175_ex31-1.htm Edgar Link pending
v393175_ex31-2.htm Edgar Link pending
v393175_ex32-1.htm Edgar Link pending